Bosh sahifa038290 ⢠KOSDAQ
add
Macrogen Inc
Yopilish kursi
17Ā 000,00Ā ā©
Kunlik diapazon
16Ā 790,00Ā ā© - 17Ā 200,00Ā ā©
Yillik diapazon
14Ā 700,00Ā ā© - 18Ā 000,00Ā ā©
Bozor kapitalizatsiyasi
185,17Ā mlrd KRW
Oʻrtacha hajm
37,78Ā ming
Narx/foyda
-
Dividend daromadliligi
1,76%
Asosiy maydon
KOSDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 49,06Ā mlrd | 48,67% |
Joriy xarajat | 17,27Ā mlrd | 25,14% |
Sof foyda | 2,46Ā mlrd | 177,27% |
Sof foyda marjasi | 5,01 | 151,97% |
Har bir ulushga tushum | ā | ā |
EBITDA | 3,81Ā mlrd | 72,55% |
Amaldagi soliq stavkasi | -2,28% | ā |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 34,59Ā mlrd | 40,60% |
Jami aktivlari | 341,60Ā mlrd | 24,59% |
Jami passivlari | 173,25Ā mlrd | 38,80% |
Umumiy kapital | 168,36Ā mlrd | ā |
Tarqatilgan aksiyalar | 10,84Ā mln | ā |
Narxi/balansdagi bahosi | 1,20 | ā |
Aktivlardan daromad | 0,84% | ā |
Kapitaldan daromad | 1,04% | ā |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,46Ā mlrd | 177,27% |
Operatsiyalardan naqd pul | 7,10Ā mlrd | 441,77% |
Sarmoyadan naqd pul | -12,18Ā mlrd | -27,34% |
Moliyadan naqd pul | 6,60Ā mlrd | -1,95% |
Naqd pulning sof oʻzgarishi | 1,94 mlrd | 143,10% |
Boʻsh pul | 2,49 mlrd | 124,72% |
Haqida
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Tashkil etilgan
5-iyn, 1997
Sayt
Xodimlar soni
500